AR063471A1 - Formulaciones para administracion parenteral de compuestos y sus usos - Google Patents

Formulaciones para administracion parenteral de compuestos y sus usos

Info

Publication number
AR063471A1
AR063471A1 ARP070103440A ARP070103440A AR063471A1 AR 063471 A1 AR063471 A1 AR 063471A1 AR P070103440 A ARP070103440 A AR P070103440A AR P070103440 A ARP070103440 A AR P070103440A AR 063471 A1 AR063471 A1 AR 063471A1
Authority
AR
Argentina
Prior art keywords
methylnaltrexone
formulation
subject
calcium
formulations
Prior art date
Application number
ARP070103440A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR063471A1 publication Critical patent/AR063471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)

Abstract

Formulaciones que proveen la efectiva provision de composiciones de metilnaltrexona. Las formulaciones provistas son utiles para prevenir, tratar, retrasar, disminuir o reducir la severidad de los efectos secundarios que resultan del uso de analgésicos opioides. Reivindicacion 1: Una composicion farmacéutica que comprende una cantidad efectiva de al menos un compuesto activo seleccionado de metilnaltrexona y una de sus sales farmacéuticamente aceptables, una sal de calcio, y un agente quelante en solucion acuosa. Reivindicacion 23: Una composicion farmacéutica de acuerdo con la reivindicacion 22, caracterizada porque uno o más de (a) a (d): la metilnaltrexona es bromuro de metilnaltrexona; el cálcico es EDTA cálcico disodico; la glicina es clorhidrato de glicina; y el portador acuoso de solucion isotonica de cloruro de sodio. Reivindicacion 31: Un método para preparar una formulacion de metilnaltrexona para la administracion parenteral, en donde el método comprende las etapas de: preparar una solucion que comprende metilnaltrexona o una de sus sales farmacéuticamente aceptables, un agente isotonico y una sal de calcio de agente quelante; y esterilizar la solucion obtenida y distribuirla en uno o más recipientes sellados. Reivindicacion 43: Un método para reducir los efectos secundarios de la terapéutica con opioides en un sujeto que recibe tratamiento opioide o el uso que comprende administrar al sujeto un régimen de formulacion de acuerdo con cualquiera de las reivindicaciones 1- 30, en donde se provee una cantidad efectiva de metilnaltrexona al sujeto. Reivindicacion 44: Un producto que comprende una formulacion de acuerdo con cualquiera de las reivindicaciones 1-30, en un recipiente sellado.
ARP070103440A 2006-08-04 2007-08-03 Formulaciones para administracion parenteral de compuestos y sus usos AR063471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83557406P 2006-08-04 2006-08-04

Publications (1)

Publication Number Publication Date
AR063471A1 true AR063471A1 (es) 2009-01-28

Family

ID=39033508

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103440A AR063471A1 (es) 2006-08-04 2007-08-03 Formulaciones para administracion parenteral de compuestos y sus usos

Country Status (25)

Country Link
US (7) US20080070975A1 (es)
EP (1) EP2046388B1 (es)
JP (1) JP5356231B2 (es)
KR (1) KR20090040248A (es)
CN (2) CN102846613A (es)
AR (1) AR063471A1 (es)
AU (1) AU2007281984B8 (es)
BR (1) BRPI0708965B8 (es)
CA (1) CA2646901C (es)
EC (1) ECSP088752A (es)
ES (1) ES2655863T3 (es)
GT (1) GT200800185A (es)
HN (1) HN2008001464A (es)
IL (2) IL194182A (es)
MX (1) MX2008011993A (es)
NO (1) NO343701B1 (es)
NZ (1) NZ597260A (es)
PE (1) PE20080741A1 (es)
PH (1) PH12013500801A1 (es)
PL (1) PL2046388T3 (es)
RU (1) RU2539387C2 (es)
SG (1) SG174030A1 (es)
TW (1) TWI489984B (es)
WO (1) WO2008019115A2 (es)
ZA (1) ZA200808203B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
PT2368553E (pt) * 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CA2865389A1 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
EP2139890B1 (en) 2007-03-29 2014-06-25 Wyeth LLC Peripheral opioid receptor antagonists and uses thereof
PE20090700A1 (es) * 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
WO2009099410A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r)-8-keto-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
AU2016201221B2 (en) * 2008-09-30 2017-08-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
AU2013203119B2 (en) * 2008-09-30 2015-12-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
MX2012001268A (es) * 2009-07-28 2012-09-12 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
NZ703564A (en) * 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
SI2616064T1 (sl) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Pripravki ketorolaka, pripravljeni za uporabo
CN102525911B (zh) * 2012-03-20 2013-09-18 南京臣功制药股份有限公司 一种溴甲纳曲酮注射液及其制备方法
CN103239452A (zh) * 2013-01-25 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种溴甲基纳曲酮药物组合物
DK2968729T3 (en) 2013-03-14 2018-12-03 Fresenius Kabi Deutschland Gmbh OXYGEN SENSITIVE PACKAGING SYSTEM
EP3143988A1 (en) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
CN107249327A (zh) 2014-10-17 2017-10-13 萨利克斯药品公司 使用甲基纳曲酮减缓肿瘤进展
CN105769755A (zh) * 2014-12-23 2016-07-20 北大方正集团有限公司 一种溴甲纳曲酮注射液及其制备方法
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
CN110960486B (zh) * 2018-09-29 2022-05-13 北京凯因科技股份有限公司 一种溴甲纳曲酮注射液组合物
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
CN111303093A (zh) * 2020-02-21 2020-06-19 重庆医药高等专科学校 一种溴甲纳曲酮杂质的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221707D0 (en) * 1992-10-15 1992-12-02 Smithkline Beecham Plc Pharmaceutical composition
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
CN1211085C (zh) * 1999-09-29 2005-07-20 宝洁公司 稳定性改善的组合物
EP2289492B1 (en) * 2002-03-14 2016-12-07 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
PT2368553E (pt) * 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS

Also Published As

Publication number Publication date
PH12013500801B1 (en) 2014-10-20
HN2008001464A (es) 2011-03-30
WO2008019115A3 (en) 2008-07-03
CN102846613A (zh) 2013-01-02
IL221795A0 (en) 2012-10-31
ES2655863T3 (es) 2018-02-22
US20230414490A1 (en) 2023-12-28
ZA200808203B (en) 2010-06-30
RU2008138266A (ru) 2010-03-27
BRPI0708965B8 (pt) 2021-05-25
CA2646901A1 (en) 2008-02-14
WO2008019115A2 (en) 2008-02-14
GT200800185A (es) 2009-08-27
NO343701B1 (no) 2019-05-13
AU2007281984B8 (en) 2014-01-09
MX2008011993A (es) 2008-10-01
TW200815007A (en) 2008-04-01
IL194182A (en) 2013-08-29
US20100249169A1 (en) 2010-09-30
EP2046388B1 (en) 2017-12-13
US20200179270A1 (en) 2020-06-11
US20220023200A1 (en) 2022-01-27
PE20080741A1 (es) 2008-08-06
JP2009545603A (ja) 2009-12-24
CN101405031A (zh) 2009-04-08
EP2046388A2 (en) 2009-04-15
TWI489984B (zh) 2015-07-01
US20080070975A1 (en) 2008-03-20
IL221795B (en) 2018-06-28
NO20083973L (no) 2009-01-06
BRPI0708965B1 (pt) 2020-01-07
ECSP088752A (es) 2008-10-31
US20150025100A1 (en) 2015-01-22
CN101405031B (zh) 2012-10-10
CA2646901C (en) 2015-12-22
JP5356231B2 (ja) 2013-12-04
SG174030A1 (en) 2011-09-29
KR20090040248A (ko) 2009-04-23
AU2007281984B2 (en) 2013-12-05
US20160338946A1 (en) 2016-11-24
PL2046388T3 (pl) 2018-04-30
NZ597260A (en) 2013-07-26
RU2539387C2 (ru) 2015-01-20
PH12013500801A1 (en) 2014-10-20
AU2007281984A1 (en) 2008-02-14
BRPI0708965A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
AR063471A1 (es) Formulaciones para administracion parenteral de compuestos y sus usos
JP6827092B2 (ja) ルリコナゾール含有外用医薬組成物
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
AR059723A2 (es) Composicion de altas dosis de ibandronato
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
MX2010008234A (es) Nueva dosificacion y formulacion.
RS53391B (en) COPD COMBINED THERAPY (CHRONIC OBSTRUCTIVE LUNG DISEASES)
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
MX2009005798A (es) Recuperacion de apoplejia.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
CO5271647A1 (es) Metodo para prevenir la diarrea
HN2006023741A (es) " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato"

Legal Events

Date Code Title Description
FB Suspension of granting procedure